Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer - PubMed Setidegrasib was associated with antitumor activity and a low incidence of treatment discontinuation due to adverse events in patients with previously treated advanced <i>KRAS</i> p.G12D-mutated NSCLC or pancreatic ductal adenocarcinoma. (Funded by Astellas Pharma; ClinicalTrials.gov number, NCT0538 …

A first-in-class #KRAS G12D-targeted protein degrader active in #lung and #pancreatic #cancer patients: pubmed.ncbi.nlm.nih.gov/41879829/

A large pan‑cancer analysis of 1667 metastatic tumors shows KRAS aberrations in 28.1%, dominated by G12D, G12V and G13D. Mutation type influenced survival, and KRAS amplification varied across tumor types.
buff.ly/ClRCkHG
#KRAS #Oncology #NGS #PrecisionMedicine #TherAdvMedOnc

"Be here now, in the moment." Terri Conneran

Thank you for this amazing presentation!

#LungCancer #PatientAdvocate #KRAS #LungCancerSurvivor #TargetedTherapies #GRACE #KRASKickers

Why is it important to know the #KRAS subtype of a patient with #LungCancer?

Dr. Christina Baik explains everything you need to know about KRAS, BRAF, and more in our Lung Cancer Targeted Therapies OncTalk.

Don’t miss it!
Register here: give.cancergrace.org/event/lung-c...

Now presenting Dr. Christina Baik:

"KRAS and BRAF mutated NSCLC".

#TargetedTherapies #LungCancer #GRACE #KRAS #NSCLC #BRAF

D3 Bio Showcases Transformative KRAS Pipeline at AACR 2026 Meeting in San Diego D3 Bio Inc will present groundbreaking data on its KRAS pipeline at AACR 2026, highlighting innovative therapies for cancer treatments.

D3 Bio Showcases Transformative KRAS Pipeline at AACR 2026 Meeting in San Diego #USA #San_Diego #oncology #D3_Bio #KRAS

Remembering Tige Andrews, born March 19, 1920 and passed away January 27, 2007.

Full Post
www.facebook.com/photo/?fbid=...

. #TodayInNerdHistory #March19 #tigeandrews #startrek #TheModSquad #kras #fridayschild #Klingon #birthday #History #News #OTD #FYP #nerd .

🚀From Bench to Paper | Targeting #ATF4 in Elderly #KRAS #LungCancer
Age reshapes tumors: slows growth but boosts metastasis via integrated stress response. ATF4 drives plasticity; targeting ISR-ATF4 blocks spread&exposes glutamine vulnerability. High ATF4 links to poor survival—promising target.

RESEARCH PAPER: Combinatorial use of VHL and KEAP1 PROTACs reveals unexpected synergy and hook effect relief
By Islam et al., and Luca Busino
➡️ https://genesdev.cshlp.org/content/40/5-6/308.abstract

Penn Medicine
#PROTAC #KRAS #cancer #cancertherapy

Emerging landscape of KRAS inhibitors in cancer treatment Alterations in KRAS, NRAS, and HRAS occur in roughly 20% of patients with cancer, making RAS one of the most intensively studied oncogenic targets. Th…

Nice review of #KRAS inhibitors: www.sciencedirect.com/science/arti...

Interesting that MRTX1133 development halted due to PK - with improved pre-clin testing, PK issues rarely lead to failure in trials

And KRAS amp seems to be major mech. of resistance - how can we exploit/prevent this?

5 innovadores medicamentos chinos, incluyendo inhibidores de:
🧬 KRAS G12C
🧬 EGFR de tercera generación
🧬 EGFR exon 20

#Fulzerasib #Sunvozertinib #Limertinib #Glecirasib #Garsorasib #Cáncer #Oncología #TerapiaDirigida #InnovaciónMédica #KRAS
#KRASG12C #EGFR #EGFRexon20 #DengYueMedicinasEnHongKong

🎯 4 dianas clave.
🧬 Tratamiento de precisión.
🌍 Impacto global.

📎 Más información: dengyuepharma.com
📧 info@dengyuemed.com
#CáncerDePulmón #CáncerDePulmónNoMicrocítico #NSCLC #Oncología #OncologíaClínica #SaludGlobal #EGFR #ALK #PD1 #PDL1 #KRAS #KRASG12C #DengYueMedicinasEnHongKong

ASCO Publications

Mutaciones KRAS específicas de codón afectan las variables del adenocarcinoma ductal pancreático según la etapa de enfermedad al momento del diagnóstico #KRAS #PDAC ascopubs.org/doi/full/10....

🧬 Oncogenic KRAS mutations (pancreatic, colorectal, lung cancers) stabilize these complexes, sustaining growth signalling.

Explore RAS at the complex level → new therapeutic insights.

#RAS #KRAS #RASopathies #CancerBiology #ComplexPortal

Support free patient education — donate today.

#LungCancer #KRAS #PatientAdvocacy

🆕 ADVANCE ONLINE 🆕

RESEARCH PAPER: Combinatorial use of VHL and KEAP1 PROTACs reveals unexpected synergy and hook effect relief
By Islam et al., and Luca Busino
➡️ genesdev.cshlp.org/content/early/2025/12/08...


#PROTAC #KRAS #cancer #cancertherapy

#CancerCure #InnovationInMedicine #Biomedicine #FutureMedicine #HealthTech #LifeSavingResearch #CancerAwareness #KRAS #ExperimentalTherapy #DrugDiscovery #PreclinicalResearch #TranslationalMedicine #ScienceNews #GlobalHealth #FightCancer

Login / Sign Up – The Oncology Network Free access for registered Healthcare Professionals.

Intriguing new research: Triple-targeted therapy shows unprecedented efficacy in early pancreatic cancer models. Read here: t.ly/kTeMr #PDAC #KRAS #STAT3 #EGFR #OncologyNews #OncologyNetworkAustralia #Spain #CNIO #OncSky #MedSky #CanSky

Synapse: Your Connection to our MSK Authors
Meet: Ethan Chi Ho Tse
Research Focus: Graduate Studies; NE WGS Student

Clinical and Molecular Characterization of KRAS-Mutated Renal Cell Carcinoma
synapse.mskcc.org/synapse/work...

#RenalCellCarcinoma #KRAS #CancerGenomics

Tumore al pancreas: la cura spagnola funziona davvero? Tripla terapia sperimentale regredisce il tumore al pancreas nei topi e frena le resistenze: che cosa cambia ora per i pazienti e la ricerca. Una combinazione farmacologica sperimentale ha eliminato t...

Tumore al pancreas: la cura spagnola funziona davvero? #TumorePancreas #Cancro #Oncologia #RicercaMedica #TriplaTerapia #KRAS #STAT3 #EGFR #Barbacid #PDAC #Salute #ClinicalTrials #Italia #Domandalo domandalo.com/spagna-cura-...

¿Cura del cáncer de páncreas? El CNIO borra tumores en ratón CNIO y Barbacid borran tumores de páncreas en ratones sin resistencias con triple terapia; claves, cifras en España y el salto a la clínica. El Centro Nacional de Investigaciones Oncológicas (CNIO) ha...

¿Cura del cáncer de páncreas? El CNIO borra tumores en ratón #CancerDePancreas #CNIO #MarianoBarbacid #Oncologia #Investigacion #Salud #Ciencia #TerapiasDirigidas #KRAS #Medicina #España #27deenero #felizmartes #PNAS #REDECAN donporque.com/cura-del-can...

PAQ Therapeutics Secures $77 Million to Advance Cancer Treatment and Doses First Patient in Innovative Trial PAQ Therapeutics has announced a Series B extension funding totaling $77 million and has initiated patient dosing for its Phase 1 trial of PT0511, aimed at treating KRAS-driven cancers.

PAQ Therapeutics Secures $77 Million to Advance Cancer Treatment and Doses First Patient in Innovative Trial #USA #Burlington #PAQ_Therapeutics #KRAS #PT0511

KRAS Inhibitors: Targeting the 'Undruggable' Mutation in 2025 and Beyond Your Science-based Guide to Wellness, Diet and Lifestyle Medicine

KRAS Inhibitors: Targeting the 'Undruggable' Mutation in 2026 and Beyond Once deemed "undruggable" due to its smooth surface and high affinity for GTP, the KRAS oncogene has become ...

#cancer #KRAS #inhibitors #pharma

Origin | Interest | Match

KRAS Inhibitors: Targeting the 'Undruggable' Mutation in 2025 and Beyond Your Science-based Guide to Wellness, Diet and Lifestyle Medicine

KRAS Inhibitors: Targeting the 'Undruggable' Mutation in 2026 and Beyond Once deemed "undruggable" due to its smooth surface and high affinity for GTP, the KRAS oncogene has become ...

#cancer #KRAS #inhibitors #pharma

Origin | Interest | Match

This review highlights #PDAC pathogenesis, focusing on KRAS–YAP–SFK signaling, the impact of #obesity via CREB/ATF1, and advances in therapies targeting #KRAS and YAP, while suggesting combinatorial prevention strategies. @uclacollege.bsky.social

#STTT: doi.org/10.1038/s413...

KRAS mutations matter! 🧬 In a cohort of 1667 advanced solid tumors, 28.1% had KRAS aberrations. G12D was most frequent (40.6%), and G12V/G13D linked to poor survival.
🔍 Learn more: buff.ly/Z7QSjPx
#Oncology #KRAS #CancerResearch